Syros Pharmaceuticals Q3 EPS $(0.47) Beats $(0.48) Estimate, Sales $558K Beat $440K Estimate

Syros Pharmaceuticals (NASDAQ:SYRS) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.48) by 2.08 percent. This is unchanged from the same period last year. The company

Benzinga · 11/12/2019 13:36

Syros Pharmaceuticals (NASDAQ:SYRS) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.48) by 2.08 percent. This is unchanged from the same period last year. The company reported quarterly sales of $558 thousand which beat the analyst consensus estimate of $440 thousand by 26.82 percent. This is a 35.44 percent increase over sales of $412 thousand the same period last year.